229 related articles for article (PubMed ID: 37088717)
1. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
[TBL] [Abstract][Full Text] [Related]
2. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
Yang M; Xiang H; Luo G
Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
[TBL] [Abstract][Full Text] [Related]
3. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
4. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.
Sun Y; Wang R; Sun Y; Wang L; Xue Y; Wang J; Wu T; Yin W; Qin Q; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Jul; 237():114373. PubMed ID: 35486993
[TBL] [Abstract][Full Text] [Related]
7. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
Chauhan A; Khan T
Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
[TBL] [Abstract][Full Text] [Related]
8. Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.
Cromm PM; Samarasinghe KTG; Hines J; Crews CM
J Am Chem Soc; 2018 Dec; 140(49):17019-17026. PubMed ID: 30444612
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase.
Yen-Pon E; Li B; Acebrón-Garcia-de-Eulate M; Tomkiewicz-Raulet C; Dawson J; Lietha D; Frame MC; Coumoul X; Garbay C; Etheve-Quelquejeu M; Chen H
ACS Chem Biol; 2018 Aug; 13(8):2067-2073. PubMed ID: 29897729
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs.
Qin Q; Wang R; Fu Q; Zhang G; Wu T; Liu N; Lv R; Yin W; Sun Y; Sun Y; Zhao D; Cheng M
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2241-2255. PubMed ID: 35978496
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
12. Focal adhesion kinase regulates collagen I-induced airway smooth muscle phenotype switching.
Dekkers BG; Spanjer AI; van der Schuyt RD; Kuik WJ; Zaagsma J; Meurs H
J Pharmacol Exp Ther; 2013 Jul; 346(1):86-95. PubMed ID: 23591997
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
14. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.
Wu X; Wang J; Liang Q; Tong R; Huang J; Yang X; Xu Y; Wang W; Sun M; Shi J
Biomed Pharmacother; 2022 Jul; 151():113116. PubMed ID: 35598365
[TBL] [Abstract][Full Text] [Related]
15. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis.
Zhao X; Guan JL
Adv Drug Deliv Rev; 2011 Jul; 63(8):610-5. PubMed ID: 21118706
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
17. FAK inhibitors in Cancer, a patent review.
Lv PC; Jiang AQ; Zhang WM; Zhu HL
Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs.
Gao H; Wu Y; Sun Y; Yang Y; Zhou G; Rao Y
ACS Med Chem Lett; 2020 Oct; 11(10):1855-1862. PubMed ID: 33062164
[TBL] [Abstract][Full Text] [Related]
19. FAK signaling in human cancer as a target for therapeutics.
Lee BY; Timpson P; Horvath LG; Daly RJ
Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
[TBL] [Abstract][Full Text] [Related]
20. Focal adhesion kinase inhibitors are potent anti-angiogenic agents.
Cabrita MA; Jones LM; Quizi JL; Sabourin LA; McKay BC; Addison CL
Mol Oncol; 2011 Dec; 5(6):517-26. PubMed ID: 22075057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]